Egret Therapeutics, a clinical-stage biotechnology company focused on developing transformative therapies for neurological conditions, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for EGT 101 that is being studied for the treatment of Delayed Cerebral Ischemia (DCI) following aneurysmal subarachnoid hemorrhage. The Phase I/II trial is expected to begin enrolling patients in 2023.
“We are thrilled to have received IND clearance for our program in aneurysmal subarachnoid hemorrhage,” said Daniel Chai, M.D., Co-Founder and Chief Executive Officer of Egret Therapeutics. “Clearance of this IND is a testament to the hard work and deep commitment from the Egret team in bringing drugs to the market that will help patients,” said Henry Park, Chief Financial Officer of Egret Therapeutics.
Also Read: Rigel Announces Publication of REZLIDHIA™ Phase 2 Clinical Results in Blood Advances
Among subarachnoid hemorrhage (SAH) patients who survive the initial bleed of a ruptured aneurysm, delayed cerebral ischemia (DCI) is the most important preventable cause of mortality and poor neurological outcome. “DCI prevention has been the focus of SAH research for decades, but few clinical options exist today. We are excited to move forward in our clinical development of EGT 101 with the hopes of bringing a therapy to patients where there is a high unmet need,” said Chris Jackson, M.D., Co-Founder and Chief Medical Officer of Egret Therapeutics.
Egret Therapeutics is a clinical-stage biotherapeutics company. The company is focused on developing products to address areas of clinical unmet need in neurological diseases.
SOURCE: PR Newswire